Express Scripts Holding Company
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Express Scripts Holding Company
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.
‘Essential Benefit’ Drug Coverage Protections Is Next Priority For Patient Group Behind Copay Accumulator Victory
HIV+Hepatitis Policy Institute provides CMS with a long list of plan sponsors and vendors that appear to be engaged in the practice, which the group argues circumvents the cost sharing protections provided by the Affordable Care Act for hundreds of drugs.
With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.
- Pharmacy Services, PBMs
- Other Names / Subsidiaries
- Aristotle Holding, Inc.
- Cigna Corporation
- Express Scripts, Inc.
- Medco Health Solutions, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.